Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 3/20 | 0.31 |
| ▸ | ESRRA | P11474 | 1/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142693 | 0.91 | EGLN2 (0.32) | LRRK2EGLN2CYP11B1CYP11B2AR | |
| SCHEMBL2749911 | 0.78 | CYP19A1 (0.41) | KDM4EUSP2ALDH1A1ARCYP19A1 | |
| SCHEMBL2750712 | 0.77 | LRRK2 (0.34) | LRRK2KDM4EUSP2ALDH1A1 | |
| SCHEMBL2752967 | 0.73 | LRRK2 (0.33) | LRRK2KDM4EUSP2ALDH1A1STS | |
| SCHEMBL2753435 | 0.73 | SMN1; SMN2 (0.36) | KDM4E | |
| SCHEMBL2752434 | 0.72 | KCNH2 (0.31) | — | |
| SCHEMBL2750774 | 0.71 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL2750812 | 0.70 | KDM4E (0.32) | EGLN2KDM4EALDH1A1CYP19A1 | |
| SCHEMBL2753780 | 0.70 | CASP3 (0.34) | EGLN2CYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL30488974 | 0.70 | IMPDH2 (0.45) | KDM4EUSP2ALDH1A1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178540-B2 | Pyrimidylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-05-15 | — | — | US | disclosed |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | BASF SE (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | TPMT, NISCH, PPA1 | LRRK2 3062/4885EGLN2 2114/4885CYP11B1 1841/4885 |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | PIR, PRDX4, PRDX2 | LRRK2 4181/4885EGLN2 1875/4885CYP11B1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.